| Energy balance after sodium–glucose cotransporter 2 inhibition G Ferrannini, T Hach, S Crowe, A Sanghvi, KD Hall, E Ferrannini Diabetes care 38 (9), 1730-1735, 2015 | 385 | 2015 |
| Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement … G Ferrannini, D De Bacquer, G De Backer, K Kotseva, L Mellbin, D Wood, ... Diabetes care 43 (4), 726-733, 2020 | 60 | 2020 |
| Coronary artery disease and type 2 diabetes: a proteomic study G Ferrannini, ML Manca, M Magnoni, F Andreotti, D Andreini, R Latini, ... Diabetes Care 43 (4), 843-851, 2020 | 44 | 2020 |
| Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry PM Becher, B Schrage, G Ferrannini, L Benson, J Butler, JJ Carrero, ... European Journal of Heart Failure 23 (6), 1012-1022, 2021 | 37 | 2021 |
| Genetic backgrounds determine brown remodeling of white fat in rodents G Ferrannini, M Namwanje, B Fang, M Damle, D Li, Q Liu, MA Lazar, ... Molecular metabolism 5 (10), 948-958, 2016 | 36 | 2016 |
| Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry P Vynckier, G Ferrannini, L Ryden, P Jankowski, T De Backer, S Gevaert, ... European Journal of Preventive Cardiology 29 (2), 344-351, 2022 | 33 | 2022 |
| Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population T Thorvaldsen, G Ferrannini, L Mellbin, L Benson, F Cosentino, ... Journal of Cardiac Failure 28 (7), 1050-1062, 2022 | 32 | 2022 |
| Is coronary artery disease inevitable in type 2 diabetes? From a glucocentric to a holistic view on patient management G Ferrannini, A Norhammar, V Gyberg, L Mellbin, L Ryden Diabetes Care 43 (9), 2001-2009, 2020 | 30 | 2020 |
| Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin G Ferrannini, H Gerstein, HM Colhoun, GR Dagenais, R Diaz, L Dyal, ... European Heart Journal 42 (26), 2565-2573, 2021 | 26 | 2021 |
| Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease … G Ferrannini, D De Bacquer, P Vynckier, G De Backer, V Gyberg, ... Cardiovascular Diabetology 20, 1-12, 2021 | 23 | 2021 |
| Risk factor reduction in type 2 diabetes demands a multifactorial approach L Rydén, G Ferrannini, L Mellbin European Journal of Preventive Cardiology 26 (2_suppl), 81-91, 2019 | 21 | 2019 |
| Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry D Stolfo, LH Lund, L Benson, F Lindberg, G Ferrannini, U Dahlström, ... European Journal of Heart Failure 25 (9), 1648-1658, 2023 | 16 | 2023 |
| Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility G Ferrannini, G Savarese, L Ryden Diabetes Research and Clinical Practice 175, 108796, 2021 | 16 | 2021 |
| EUROASPIRE V collaborators. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease-a persistent challenge in need … G Ferrannini, D De Bacquer, G De Backer, K Kotseva, L Mellbin, D Wood, ... Diabetes Care 43 (4), 726-733, 2020 | 15 | 2020 |
| Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance E Ferrannini, N Marx, D Andreini, B Campi, A Saba, M Gorini, ... International journal of cardiology 346, 86-92, 2022 | 13 | 2022 |
| Medical treatment in coronary patients: is there still a gender gap? results from European Society of Cardiology EUROASPIRE V registry P Vynckier, G Ferrannini, L Rydén, L Tokgözoğlu, J Bruthans, K Kotseva, ... Cardiovascular Drugs and Therapy 35, 801-808, 2021 | 13 | 2021 |
| Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data G Ferrannini, L Rydén Clinical Science 132 (18), 2003-2012, 2018 | 12 | 2018 |
| Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis G Ferrannini, LH Lund, L Benson, M Rizzo, W Almahmeed, GMC Rosano, ... European Heart Journal-Cardiovascular Pharmacotherapy 9 (1), 10-17, 2023 | 11 | 2023 |
| SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI) M Lundin, G Ferrannini, L Mellbin, I Johansson, A Norhammar, P Näsman, ... Diabetes Research and Clinical Practice 193, 110141, 2022 | 11 | 2022 |
| Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition G Ferrannini, T Hach, S Crowe, E Ferrannini Diabetologia 57, S8-S8, 2014 | 11 | 2014 |
